Novel therapies for metastatic castrate-resistant prostate cancer.

PubWeight™: 1.98‹?› | Rank: Top 2%

🔗 View Article (PMC 4176261)

Published in J Natl Cancer Inst on September 13, 2011


Farshid Dayyani1, Gary E Gallick, Christopher J Logothetis, Paul G Corn

Author Affiliations

1: Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA.

Associated clinical trials:

Abiraterone Acetate in Castration-Resistant Prostate Cancer Previously Treated With Docetaxel-Based Chemotherapy | NCT00638690

Study of Immunotherapy to Treat Advanced Prostate Cancer | NCT00861614

Phase 3 Study of Immunotherapy to Treat Advanced Prostate Cancer | NCT01057810

Abiraterone Acetate in Asymptomatic or Mildly Symptomatic Patients With Metastatic Castration-Resistant Prostate Cancer | NCT00887198

Safety and Efficacy Study of MDV3100 in Patients With Castration-Resistant Prostate Cancer Who Have Been Previously Treated With Docetaxel-based Chemotherapy (AFFIRM) | NCT00974311

A Randomized, Double-blind, Phase 3 Efficacy Trial of PROSTVAC-V/F +/- GM-CSF in Men With Asymptomatic or Minimally Symptomatic Metastatic Castrate-Resistant Prostate Cancer (Prospect) | NCT01322490

A Safety and Efficacy Study of Oral MDV3100 in Chemotherapy-Naive Patients With Progressive Metastatic Prostate Cancer (PREVAIL) | NCT01212991

Provenge® (Sipuleucel-T) Active Cellular Immunotherapy Treatment of Metastatic Prostate Cancer After Failing Hormone Therapy | NCT00065442

Study Comparing Orteronel Plus Prednisone in Patients With Metastatic Castration-Resistant Prostate Cancer | NCT01193257

Randomized Study Comparing Docetaxel Plus Dasatinib to Docetaxel Plus Placebo in Castration-resistant Prostate Cancer (READY) | NCT00744497

XRP6258 Plus Prednisone Compared to Mitoxantrone Plus Prednisone in Hormone Refractory Metastatic Prostate Cancer (TROPIC) | NCT00417079

Study Comparing Orteronel Plus Prednisone in Patients With Chemotherapy-Naive Metastatic Castration-Resistant Prostate Cancer | NCT01193244

Study of Cabozantinib (XL184) in Adults With Advanced Malignancies | NCT00940225

S0421, Docetaxel and Prednisone With or Without Atrasentan in Treating Patients With Stage IV Prostate Cancer and Bone Metastases That Did Not Respond to Previous Hormone Therapy | NCT00134056

Docetaxel and Prednisone With or Without Vaccine Therapy in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer | NCT01145508

153Sm-EDTMP With or Without a PSA/TRICOM Vaccine To Treat Men With Androgen-Insensitive Prostate Cancer | NCT00450619

Comparison of Docetaxel/Prednisone to Docetaxel/Prednisone in Combination With OGX-011 in Men With Prostate Cancer (SYNERGY) | NCT01188187

Docetaxel and Prednisone With or Without Bevacizumab in Treating Patients With Prostate Cancer That Did Not Respond to Hormone Therapy | NCT00110214

Vaccine Therapy With PROSTVAC/TRICOM and Flutamide Versus Flutamide Alone to Treat Prostate Cancer | NCT00450463

Sunitinib Plus Prednisone In Patients With Metastatic Castration-Resistant Prostate Cancer After Failure Of Docetaxel Chemotherapy (SUN 1120) | NCT00676650

A Study Evaluating the Pain Palliation Benefit of Adding Custirsen to Docetaxel Retreatment or Cabazitaxel as Second Line Therapy in Men With Metastatic Castrate Resistant Prostate Cancer (mCRPC) | NCT01083615

Study to Evaluate Safety and Effectiveness of Lenalidomide in Combination With Docetaxel and Prednisone for Patients With Castrate-Resistant Prostate Cancer (Mainsail) | NCT00988208

Vaccine Therapy in Treating Patients With Metastatic Prostate Cancer That Has Not Responded to Hormone Therapy | NCT00005947

Provenge (TM) for the Treatment of Hormone Sensitive Prostate Cancer (PROTECT) | NCT00779402

A Phase 2 Trial of Bevacizumab, Lenalidomide, Docetaxel, and Prednisone (ART-P) for Treatment of Metastatic Castrate-Resistant Prostate Cancer | NCT00942578

Safety Study of TAK-700 in Subjects With Prostate Cancer. (TAK-700) | NCT00569153

TKI258 in Castrate Resistant Prostate Cancer | NCT00831792

Immunotherapy With APC8015 (Sipuleucel-T, Provenge) for Asymptomatic, Metastatic, Hormone-Refractory Prostate Cancer | NCT01133704

Docetaxel, Thalidomide, Prednisone, and Bevacizumab to Treat Metastatic Prostate Cancer | NCT00089609

Thalidomide for the Treatment of Hormone-Dependent Prostate Cancer | NCT00004635

Study of Atrasentan in Men With Non-Metastatic, Hormone-Refractory Prostate Cancer | NCT00036556

A Study of Atrasentan in Men With Metastatic, Hormone-Refractory Prostate Cancer | NCT00036543

Articles citing this

Prostate cancer progression after androgen deprivation therapy: mechanisms of castrate resistance and novel therapeutic approaches. Oncogene (2013) 2.64

Transcriptional signatures of Ral GTPase are associated with aggressive clinicopathologic characteristics in human cancer. Cancer Res (2012) 1.00

Induction of the transcriptional repressor ZBTB4 in prostate cancer cells by drug-induced targeting of microRNA-17-92/106b-25 clusters. Mol Cancer Ther (2012) 0.96

Mesenchymal stem cells as a vector for the inflammatory prostate microenvironment. Endocr Relat Cancer (2013) 0.96

Role of proprotein convertases in prostate cancer progression. Neoplasia (2012) 0.92

Targeting bone metastases in prostate cancer: improving clinical outcome. Nat Rev Urol (2015) 0.92

Metastatic castration-resistant prostate cancer: new therapies, novel combination strategies and implications for immunotherapy. Oncogene (2013) 0.91

Paclitaxel-loaded iron platinum stealth immunomicelles are potent MRI imaging agents that prevent prostate cancer growth in a PSMA-dependent manner. Int J Nanomedicine (2012) 0.90

Advances in androgen receptor targeted therapy for prostate cancer. J Cell Physiol (2014) 0.89

Unveiling the association of STAT3 and HO-1 in prostate cancer: role beyond heme degradation. Neoplasia (2012) 0.89

The stroma-a key regulator in prostate function and malignancy. Cancers (Basel) (2012) 0.88

Combined Inhibition of IGF-1R/IR and Src family kinases enhances antitumor effects in prostate cancer by decreasing activated survival pathways. PLoS One (2012) 0.88

Combining T-cell immunotherapy and anti-androgen therapy for prostate cancer. Prostate Cancer Prostatic Dis (2013) 0.87

Parathyroid hormone-related protein drives a CD11b+Gr1+ cell-mediated positive feedback loop to support prostate cancer growth. Cancer Res (2013) 0.87

Panobinostat synergizes with zoledronic acid in prostate cancer and multiple myeloma models by increasing ROS and modulating mevalonate and p38-MAPK pathways. Cell Death Dis (2013) 0.85

Chitosan nanoparticle-mediated delivery of miRNA-34a decreases prostate tumor growth in the bone and its expression induces non-canonical autophagy. Oncotarget (2015) 0.85

Systemic GLIPR1-ΔTM protein as a novel therapeutic approach for prostate cancer. Int J Cancer (2013) 0.84

N-linked glycosylation supports cross-talk between receptor tyrosine kinases and androgen receptor. PLoS One (2013) 0.82

A 3D in vitro model of patient-derived prostate cancer xenograft for controlled interrogation of in vivo tumor-stromal interactions. Biomaterials (2015) 0.81

STAMP2 increases oxidative stress and is critical for prostate cancer. EMBO Mol Med (2015) 0.81

The biology of castration-resistant prostate cancer. Curr Probl Cancer (2014) 0.80

Response in bone turnover markers during therapy predicts overall survival in patients with metastatic prostate cancer: analysis of three clinical trials. Br J Cancer (2012) 0.80

Chemical biology drug sensitivity screen identifies sunitinib as synergistic agent with disulfiram in prostate cancer cells. PLoS One (2012) 0.80

Transcriptional activation by NFκB increases perlecan/HSPG2 expression in the desmoplastic prostate tumor microenvironment. J Cell Biochem (2014) 0.80

SRC family kinase FYN promotes the neuroendocrine phenotype and visceral metastasis in advanced prostate cancer. Oncotarget (2015) 0.79

Hormonal Therapeutics Enzalutamide and Abiraterone Acetate in the Treatment of Metastatic Castration-Resistant Prostate Cancer (mCRPC) Post-docetaxel-an Indirect Comparison. Clin Med Insights Oncol (2014) 0.79

Identification of Bone-Derived Factors Conferring De Novo Therapeutic Resistance in Metastatic Prostate Cancer. Cancer Res (2015) 0.79

Androgen receptor in human endothelial cells. J Endocrinol (2015) 0.79

A prodrug-doped cellular Trojan Horse for the potential treatment of prostate cancer. Biomaterials (2016) 0.79

Averaged differential expression for the discovery of biomarkers in the blood of patients with prostate cancer. PLoS One (2012) 0.78

Cabozantinib resolves bone scans in tumor-naïve mice harboring skeletal injuries. Mol Imaging (2014) 0.78

Increased serum insulin-like growth factor-1 levels are associated with prolonged response to dasatinib-based regimens in metastatic prostate cancer. Prostate (2013) 0.78

A changing landscape in castration-resistant prostate cancer treatment. Front Endocrinol (Lausanne) (2012) 0.78

Multimodal imaging guided preclinical trials of vascular targeting in prostate cancer. Oncotarget (2015) 0.77

Personalized prostate cancer therapy based on systems analysis of the apoptosis regulatory network. Asian J Androl (2015) 0.77

lncRNA HOXD-AS1 Regulates Proliferation and Chemo-Resistance of Castration-Resistant Prostate Cancer via Recruiting WDR5. Mol Ther (2017) 0.77

Skp2 deficiency restricts the progression and stem cell features of castration-resistant prostate cancer by destabilizing Twist. Oncogene (2017) 0.76

Re: novel therapies for metastatic castrate-resistant prostate cancer. J Natl Cancer Inst (2012) 0.75

The combination of serum insulin, osteopontin, and hepatocyte growth factor predicts time to castration-resistant progression in androgen dependent metastatic prostate cancer- an exploratory study. BMC Cancer (2016) 0.75

A tight junction between E-Cadherin and the prostate tumor suppressor SPDEF. Asian J Androl (2013) 0.75

The potential of organoids in urological cancer research. Nat Rev Urol (2017) 0.75

Articles cited by this

Cancer statistics, 2010. CA Cancer J Clin (2010) 103.28

Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med (2010) 67.34

Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med (2004) 32.09

Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med (2010) 29.75

Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med (2011) 27.58

Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med (2004) 23.44

Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science (2005) 23.44

Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet (2010) 19.74

Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. J Clin Oncol (2008) 18.54

Met, metastasis, motility and more. Nat Rev Mol Cell Biol (2003) 14.30

Development of a second-generation antiandrogen for treatment of advanced prostate cancer. Science (2009) 13.87

The distribution of secondary growths in cancer of the breast. 1889. Cancer Metastasis Rev (1989) 13.15

A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J Natl Cancer Inst (2002) 12.07

Overriding imatinib resistance with a novel ABL kinase inhibitor. Science (2004) 11.83

Angiogenesis: an organizing principle for drug discovery? Nat Rev Drug Discov (2007) 11.46

Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study. Lancet (2011) 11.28

Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven. J Clin Oncol (2008) 10.91

Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1-2 study. Lancet (2010) 10.79

Maintenance of intratumoral androgens in metastatic prostate cancer: a mechanism for castration-resistant tumor growth. Cancer Res (2008) 10.66

Biology of progressive, castration-resistant prostate cancer: directed therapies targeting the androgen-receptor signaling axis. J Clin Oncol (2005) 10.48

Overall survival analysis of a phase II randomized controlled trial of a Poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer. J Clin Oncol (2010) 9.86

Natural history of early, localized prostate cancer. JAMA (2004) 7.44

Selective inhibition of CYP17 with abiraterone acetate is highly active in the treatment of castration-resistant prostate cancer. J Clin Oncol (2009) 6.68

Clinical translation of angiogenesis inhibitors. Nat Rev Cancer (2002) 6.58

Significant and sustained antitumor activity in post-docetaxel, castration-resistant prostate cancer with the CYP17 inhibitor abiraterone acetate. J Clin Oncol (2010) 5.86

Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer. J Clin Oncol (2006) 5.72

Outcomes of localized prostate cancer following conservative management. JAMA (2009) 5.57

Characterization of ERG, AR and PTEN gene status in circulating tumor cells from patients with castration-resistant prostate cancer. Cancer Res (2009) 4.68

The tumor microenvironment and its role in promoting tumor growth. Oncogene (2008) 4.66

Phase II multicenter study of abiraterone acetate plus prednisone therapy in patients with docetaxel-treated castration-resistant prostate cancer. J Clin Oncol (2010) 4.64

Integrated data from 2 randomized, double-blind, placebo-controlled, phase 3 trials of active cellular immunotherapy with sipuleucel-T in advanced prostate cancer. Cancer (2009) 4.12

Risk profiles and treatment patterns among men diagnosed as having prostate cancer and a prostate-specific antigen level below 4.0 ng/ml. Arch Intern Med (2010) 3.85

Randomized, double-blind, placebo-controlled phase III trial comparing docetaxel and prednisone with or without bevacizumab in men with metastatic castration-resistant prostate cancer: CALGB 90401. J Clin Oncol (2012) 3.73

Immunologic and prognostic factors associated with overall survival employing a poxviral-based PSA vaccine in metastatic castrate-resistant prostate cancer. Cancer Immunol Immunother (2009) 3.70

Antiangiogenic therapy: impact on invasion, disease progression, and metastasis. Nat Rev Clin Oncol (2011) 3.58

Detection of organ-confined prostate cancer is increased through prostate-specific antigen-based screening. JAMA (1993) 3.46

Phenotypic heterogeneity of end-stage prostate carcinoma metastatic to bone. Hum Pathol (2003) 3.17

Randomized phase II trial of docetaxel plus thalidomide in androgen-independent prostate cancer. J Clin Oncol (2004) 3.16

A phase 3 randomized controlled trial of the efficacy and safety of atrasentan in men with metastatic hormone-refractory prostate cancer. Cancer (2007) 3.15

Osteoblasts in prostate cancer metastasis to bone. Nat Rev Cancer (2005) 2.86

Metastatic patterns of prostatic cancer. Correlation between sites and number of organs involved. Cancer (1984) 2.78

A pilot trial of CTLA-4 blockade with human anti-CTLA-4 in patients with hormone-refractory prostate cancer. Clin Cancer Res (2007) 2.71

Tumor regression and growth rates determined in five intramural NCI prostate cancer trials: the growth rate constant as an indicator of therapeutic efficacy. Clin Cancer Res (2010) 2.45

Molecular insights into prostate cancer progression: the missing link of tumor microenvironment. J Urol (2005) 2.43

Potentiating endogenous antitumor immunity to prostate cancer through combination immunotherapy with CTLA4 blockade and GM-CSF. Cancer Res (2009) 2.32

Phase I and pharmacokinetic study of XRP6258 (RPR 116258A), a novel taxane, administered as a 1-hour infusion every 3 weeks in patients with advanced solid tumors. Clin Cancer Res (2009) 2.30

The contemporary concept of significant versus insignificant prostate cancer. Eur Urol (2011) 2.29

Adaptive therapy for androgen-independent prostate cancer: a randomized selection trial of four regimens. J Natl Cancer Inst (2007) 2.24

A causal role for endothelin-1 in the pathogenesis of osteoblastic bone metastases. Proc Natl Acad Sci U S A (2003) 2.23

A randomized phase II trial of thalidomide, an angiogenesis inhibitor, in patients with androgen-independent prostate cancer. Clin Cancer Res (2001) 2.05

The androgen receptor negatively regulates the expression of c-Met: implications for a novel mechanism of prostate cancer progression. Cancer Res (2007) 1.99

Phase II study of dasatinib in patients with metastatic castration-resistant prostate cancer. Clin Cancer Res (2009) 1.99

VEGF and c-Met blockade amplify angiogenesis inhibition in pancreatic islet cancer. Cancer Res (2011) 1.92

Androgen receptor-negative human prostate cancer cells induce osteogenesis in mice through FGF9-mediated mechanisms. J Clin Invest (2008) 1.87

Clinical safety of a viral vector based prostate cancer vaccine strategy. J Urol (2007) 1.84

Randomized phase II study of docetaxel and prednisone with or without OGX-011 in patients with metastatic castration-resistant prostate cancer. J Clin Oncol (2010) 1.76

Platelet-derived growth factor receptor inhibition and chemotherapy for castration-resistant prostate cancer with bone metastases. Clin Cancer Res (2007) 1.74

A phase I trial of pox PSA vaccines (PROSTVAC-VF) with B7-1, ICAM-1, and LFA-3 co-stimulatory molecules (TRICOM) in patients with prostate cancer. J Transl Med (2006) 1.66

Markers of bone metabolism and survival in men with hormone-refractory metastatic prostate cancer. Clin Cancer Res (2006) 1.65

The bone microenvironment in metastasis; what is special about bone? Cancer Metastasis Rev (2008) 1.63

CYP17 inhibition as a hormonal strategy for prostate cancer. Nat Clin Pract Urol (2008) 1.49

Pathogenesis and treatment of prostate cancer bone metastases: targeting the lethal phenotype. J Clin Oncol (2005) 1.44

Differential androgen receptor signals in different cells explain why androgen-deprivation therapy of prostate cancer fails. Oncogene (2010) 1.43

New bone formation in an osteoblastic tumor model is increased by endothelin-1 overexpression and decreased by endothelin A receptor blockade. Urology (1999) 1.41

A new therapy paradigm for prostate cancer founded on clinical observations. Clin Cancer Res (2010) 1.32

Docetaxel-based combination therapy for castration-resistant prostate cancer. Ann Oncol (2010) 1.27

Management of advanced prostate cancer after first-line chemotherapy. J Clin Oncol (2005) 1.26

The role of tumor microenvironment in prostate cancer bone metastasis. J Cell Biochem (2007) 1.26

The effects of four different tyrosine kinase inhibitors on medullary and papillary thyroid cancer cells. J Clin Endocrinol Metab (2011) 1.25

Neuroendocrine prostate cancer xenografts with large-cell and small-cell features derived from a single patient's tumor: morphological, immunohistochemical, and gene expression profiles. Prostate (2010) 1.24

Dasatinib inhibits the growth of prostate cancer in bone and provides additional protection from osteolysis. Br J Cancer (2009) 1.23

Therapeutic targeting of the prostate cancer microenvironment. Nat Rev Urol (2010) 1.22

Targeting the cytoprotective chaperone, clusterin, for treatment of advanced cancer. Clin Cancer Res (2010) 1.22

A randomized phase II trial of docetaxel (taxotere) plus thalidomide in androgen-independent prostate cancer. Semin Oncol (2001) 1.21

Enhanced radiation sensitivity in prostate cancer by inhibition of the cell survival protein clusterin. Clin Cancer Res (2002) 1.20

Docetaxel plus oblimersen sodium (Bcl-2 antisense oligonucleotide): an EORTC multicenter, randomized phase II study in patients with castration-resistant prostate cancer. Ann Oncol (2009) 1.19

Castration-resistant prostate cancer: targeting androgen metabolic pathways in recurrent disease. Urol Oncol (2009) 1.14

Prostate cancer and the met hepatocyte growth factor receptor. Adv Cancer Res (2004) 1.13

Phase I study of oral lenalidomide in patients with refractory metastatic cancer. J Clin Pharmacol (2009) 1.11

Endothelin-1 from prostate cancer cells is enhanced by bone contact which blocks osteoclastic bone resorption. Br J Cancer (2000) 1.09

Efficacy of c-Met inhibitor for advanced prostate cancer. BMC Cancer (2010) 1.03

Mechanisms of tumor escape from the immune system: adenosine-producing Treg, exosomes and tumor-associated TLRs. Bull Cancer (2011) 0.99

An open-label phase II study of low-dose thalidomide in androgen-independent prostate cancer. Br J Cancer (2003) 0.98

Localization of androgen receptor expression in human bone marrow. J Pathol (2001) 0.97

Use of antisense oligonucleotides targeting the antiapoptotic gene, clusterin/testosterone-repressed prostate message 2, to enhance androgen sensitivity and chemosensitivity in prostate cancer. Urology (2001) 0.97

Sipuleucel-T (APC8015) for prostate cancer. Expert Rev Anticancer Ther (2006) 0.94

Cancer interaction with the bone microenvironment: a workshop of the National Institutes of Health Tumor Microenvironment Study Section. Am J Pathol (2006) 0.87

Custirsen (OGX-011): a second-generation antisense inhibitor of clusterin for the treatment of cancer. Expert Opin Investig Drugs (2008) 0.86

Randomized phase II study of atrasentan alone or in combination with zoledronic acid in men with metastatic prostate cancer. Cancer (2006) 0.85

Cross-talk between cellular stress, cell cycle and anticancer agents: mechanistic aspects. Curr Med Chem Anticancer Agents (2002) 0.84

Taxane refractory prostate cancer. J Urol (2007) 0.84

The current and emerging role of immunotherapy in prostate cancer. Clin Genitourin Cancer (2010) 0.83

Multiple cycles of intermittent chemotherapy in metastatic androgen-independent prostate cancer. Br J Cancer (2004) 0.80

Angiogenesis inhibition in the treatment of prostate cancer. Anticancer Agents Med Chem (2009) 0.78

Articles by these authors

Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med (2011) 27.58

Abiraterone in metastatic prostate cancer without previous chemotherapy. N Engl J Med (2012) 15.69

Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol (2012) 6.49

Personalized oncology through integrative high-throughput sequencing: a pilot study. Sci Transl Med (2011) 5.82

Src family kinases in tumor progression and metastasis. Cancer Metastasis Rev (2003) 4.62

Effects of abiraterone acetate on androgen signaling in castrate-resistant prostate cancer in bone. J Clin Oncol (2011) 4.57

Epithelial to mesenchymal transition contributes to drug resistance in pancreatic cancer. Cancer Res (2009) 4.19

Development and characterization of gemcitabine-resistant pancreatic tumor cells. Ann Surg Oncol (2007) 4.12

Cabozantinib in patients with advanced prostate cancer: results of a phase II randomized discontinuation trial. J Clin Oncol (2012) 3.92

Steps toward mapping the human vasculature by phage display. Nat Med (2002) 3.82

Acquisition of epithelial-mesenchymal transition phenotype of gemcitabine-resistant pancreatic cancer cells is linked with activation of the notch signaling pathway. Cancer Res (2009) 3.57

Docetaxel and dasatinib or placebo in men with metastatic castration-resistant prostate cancer (READY): a randomised, double-blind phase 3 trial. Lancet Oncol (2013) 3.38

Generation of orthotopic and heterotopic human pancreatic cancer xenografts in immunodeficient mice. Nat Protoc (2009) 3.36

Fingerprinting the circulating repertoire of antibodies from cancer patients. Nat Biotechnol (2002) 3.32

Phase I trial of the proteasome inhibitor bortezomib in patients with advanced solid tumors with observations in androgen-independent prostate cancer. J Clin Oncol (2004) 3.02

Pharmacological inactivation of Skp2 SCF ubiquitin ligase restricts cancer stem cell traits and cancer progression. Cell (2013) 2.81

Preoperative CTLA-4 blockade: tolerability and immune monitoring in the setting of a presurgical clinical trial. Clin Cancer Res (2010) 2.73

Targeting SRC family kinases inhibits growth and lymph node metastases of prostate cancer in an orthotopic nude mouse model. Cancer Res (2008) 2.59

HIF-1alpha, STAT3, CBP/p300 and Ref-1/APE are components of a transcriptional complex that regulates Src-dependent hypoxia-induced expression of VEGF in pancreatic and prostate carcinomas. Oncogene (2005) 2.53

ALDH activity selectively defines an enhanced tumor-initiating cell population relative to CD133 expression in human pancreatic adenocarcinoma. PLoS One (2011) 2.49

Selenium and vitamin E: cell type- and intervention-specific tissue effects in prostate cancer. J Natl Cancer Inst (2009) 2.34

Phase II study of abiraterone acetate in chemotherapy-naive metastatic castration-resistant prostate cancer displaying bone flare discordant with serologic response. Clin Cancer Res (2011) 2.23

Obesity, weight gain, and risk of biochemical failure among prostate cancer patients following prostatectomy. Clin Cancer Res (2005) 2.14

Inhibition of SRC expression and activity inhibits tumor progression and metastasis of human pancreatic adenocarcinoma cells in an orthotopic nude mouse model. Am J Pathol (2006) 2.07

Activation of Src kinase in primary colorectal carcinoma: an indicator of poor clinical prognosis. Cancer (2002) 2.03

Identification of cell cycle regulatory genes as principal targets of p53-mediated transcriptional repression. J Biol Chem (2006) 2.01

Regulation of Cdc25C by ERK-MAP kinases during the G2/M transition. Cell (2007) 1.97

Prostate carcinoma with testicular or penile metastases. Clinical, pathologic, and immunohistochemical features. Cancer (2002) 1.95

Bayesian and frequentist two-stage treatment strategies based on sequential failure times subject to interval censoring. Stat Med (2007) 1.92

Resistance to BRAF inhibition in BRAF-mutant colon cancer can be overcome with PI3K inhibition or demethylating agents. Clin Cancer Res (2012) 1.92

Adenoviral-mediated expression of MMAC/PTEN inhibits proliferation and metastasis of human prostate cancer cells. Clin Cancer Res (2002) 1.88

Efficacy and antivascular effects of EphA2 reduction with an agonistic antibody in ovarian cancer. J Natl Cancer Inst (2006) 1.87

Androgen receptor-negative human prostate cancer cells induce osteogenesis in mice through FGF9-mediated mechanisms. J Clin Invest (2008) 1.87

Molecular mechanisms of resistance to therapies targeting the epidermal growth factor receptor. Clin Cancer Res (2005) 1.83

Reduced c-Met expression by an adenovirus expressing a c-Met ribozyme inhibits tumorigenic growth and lymph node metastases of PC3-LN4 prostate tumor cells in an orthotopic nude mouse model. Clin Cancer Res (2003) 1.80

Results of a phase II study with doxorubicin, etoposide, and cisplatin in patients with fully characterized small-cell carcinoma of the prostate. J Clin Oncol (2002) 1.79

Activated SRC protein tyrosine kinase is overexpressed in late-stage human ovarian cancers. Gynecol Oncol (2003) 1.75

Platelet-derived growth factor receptor inhibition and chemotherapy for castration-resistant prostate cancer with bone metastases. Clin Cancer Res (2007) 1.74

Stem-cell origin of metastasis and heterogeneity in solid tumours. Lancet Oncol (2002) 1.74

Treatment for advanced tumors: SRC reclaims center stage. Clin Cancer Res (2006) 1.74

Src activation regulates anoikis in human colon tumor cell lines. Oncogene (2002) 1.70

The role of the guanine nucleotide exchange factor Tiam1 in cellular migration, invasion, adhesion and tumor progression. Breast Cancer Res Treat (2004) 1.69

Early predicted time to normalization of tumor markers predicts outcome in poor-prognosis nonseminomatous germ cell tumors. J Clin Oncol (2004) 1.67

Phase II presurgical feasibility study of bevacizumab in untreated patients with metastatic renal cell carcinoma. J Clin Oncol (2009) 1.67

Cadherin-11 promotes the metastasis of prostate cancer cells to bone. Mol Cancer Res (2008) 1.67

Src activation by β-adrenoreceptors is a key switch for tumour metastasis. Nat Commun (2013) 1.62

Impact of insulin-like growth factor receptor-I function on angiogenesis, growth, and metastasis of colon cancer. Lab Invest (2002) 1.57

Combinatorial screenings in patients: the interleukin-11 receptor alpha as a candidate target in the progression of human prostate cancer. Cancer Res (2004) 1.56

Nuclear PTEN-mediated growth suppression is independent of Akt down-regulation. Mol Cell Biol (2005) 1.55

Stress hormones regulate interleukin-6 expression by human ovarian carcinoma cells through a Src-dependent mechanism. J Biol Chem (2007) 1.54

CXCL-12/stromal cell-derived factor-1alpha transactivates HER2-neu in breast cancer cells by a novel pathway involving Src kinase activation. Cancer Res (2005) 1.54

Synergistic activity of the SRC family kinase inhibitor dasatinib and oxaliplatin in colon carcinoma cells is mediated by oxidative stress. Cancer Res (2009) 1.54

Addition of estramustine to chemotherapy and survival of patients with castration-refractory prostate cancer: a meta-analysis of individual patient data. Lancet Oncol (2007) 1.53

Platinum-based chemotherapy for variant castrate-resistant prostate cancer. Clin Cancer Res (2013) 1.53

Hedgehog signaling inhibition by the small molecule smoothened inhibitor GDC-0449 in the bone forming prostate cancer xenograft MDA PCa 118b. Prostate (2012) 1.53

Abiraterone acetate plus prednisone versus prednisone alone in chemotherapy-naive men with metastatic castration-resistant prostate cancer: patient-reported outcome results of a randomised phase 3 trial. Lancet Oncol (2013) 1.51

Epithelial to mesenchymal transition in head and neck squamous carcinoma: association of Src activation with E-cadherin down-regulation, vimentin expression, and aggressive tumor features. Cancer (2008) 1.50

Src continues aging: current and future clinical directions. Clin Cancer Res (2007) 1.50

Dasatinib combined with docetaxel for castration-resistant prostate cancer: results from a phase 1-2 study. Cancer (2011) 1.49

Cadherin-11 increases migration and invasion of prostate cancer cells and enhances their interaction with osteoblasts. Cancer Res (2010) 1.46

Pathogenesis and treatment of prostate cancer bone metastases: targeting the lethal phenotype. J Clin Oncol (2005) 1.44

Initial modulation of the tumor microenvironment accounts for thalidomide activity in prostate cancer. Clin Cancer Res (2007) 1.42

Prostate cancer cells-osteoblast interaction shifts expression of growth/survival-related genes in prostate cancer and reduces expression of osteoprotegerin in osteoblasts. Clin Cancer Res (2003) 1.42

Alphavbeta3 integrin antagonist S247 decreases colon cancer metastasis and angiogenesis and improves survival in mice. Cancer Res (2003) 1.41

Phase III trial of androgen ablation with or without three cycles of systemic chemotherapy for advanced prostate cancer. J Clin Oncol (2008) 1.40

Regulatory role of c-Met in insulin-like growth factor-I receptor-mediated migration and invasion of human pancreatic carcinoma cells. Mol Cancer Ther (2006) 1.39

PCAT-1, a long noncoding RNA, regulates BRCA2 and controls homologous recombination in cancer. Cancer Res (2014) 1.39

Is there a role for surgery in the management of metastatic urothelial cancer? The M. D. Anderson experience. J Urol (2004) 1.39

Antiangiogenic and antitumor effects of SRC inhibition in ovarian carcinoma. Cancer Res (2006) 1.38

Expression and activity of SRC regulate interleukin-8 expression in pancreatic adenocarcinoma cells: implications for angiogenesis. Cancer Res (2005) 1.34

Steps in prostate cancer progression that lead to bone metastasis. Int J Cancer (2011) 1.34

A new therapy paradigm for prostate cancer founded on clinical observations. Clin Cancer Res (2010) 1.32

SRC family nonreceptor tyrosine kinases as molecular targets for cancer therapy. Anticancer Agents Med Chem (2007) 1.32

Involvement of the conserved adaptor protein Alix in actin cytoskeleton assembly. J Biol Chem (2006) 1.30

AFAP-110 is overexpressed in prostate cancer and contributes to tumorigenic growth by regulating focal contacts. J Clin Invest (2007) 1.30

Bortezomib as a potential treatment for prostate cancer. Cancer Res (2004) 1.29

Tiam1 regulates cell adhesion, migration and apoptosis in colon tumor cells. Clin Exp Metastasis (2006) 1.26

The role of HGF/c-Met signaling in prostate cancer progression and c-Met inhibitors in clinical trials. Expert Opin Investig Drugs (2011) 1.24

BMP4 promotes prostate tumor growth in bone through osteogenesis. Cancer Res (2011) 1.23

Molecular profiling of direct xenograft tumors established from human pancreatic adenocarcinoma after neoadjuvant therapy. Ann Surg Oncol (2011) 1.23

Adipose tissue-derived stem cells promote prostate tumor growth. Prostate (2010) 1.22

GWAS meets microarray: are the results of genome-wide association studies and gene-expression profiling consistent? Prostate cancer as an example. PLoS One (2009) 1.20

Focus on TILs: Prognostic significance of tumor infiltrating lymphocytes in human bladder cancer. Cancer Immun (2007) 1.19

Molecular classification of prostate cancer progression: foundation for marker-driven treatment of prostate cancer. Cancer Discov (2013) 1.18

Cyclooxygenase-2 is up-regulated by interleukin-1 beta in human colorectal cancer cells via multiple signaling pathways. Cancer Res (2003) 1.17

AFAP-110 is required for actin stress fiber formation and cell adhesion in MDA-MB-231 breast cancer cells. J Cell Physiol (2007) 1.17

Modeling a lethal prostate cancer variant with small-cell carcinoma features. Clin Cancer Res (2011) 1.15

Hypoxic regulation of mRNA expression. Cell Cycle (2008) 1.14

Cell cycle-dependent nuclear export of phosphatase and tensin homologue tumor suppressor is regulated by the phosphoinositide-3-kinase signaling cascade. Cancer Res (2007) 1.14

NY-ESO-1 DNA vaccine induces T-cell responses that are suppressed by regulatory T cells. Clin Cancer Res (2009) 1.14

c-Src regulates constitutive and EGF-mediated VEGF expression in pancreatic tumor cells through activation of phosphatidyl inositol-3 kinase and p38 MAPK. Pancreas (2005) 1.14

AP23846, a novel and highly potent Src family kinase inhibitor, reduces vascular endothelial growth factor and interleukin-8 expression in human solid tumor cell lines and abrogates downstream angiogenic processes. Mol Cancer Ther (2005) 1.13

Pre-clinical mouse models of human prostate cancer and their utility in drug discovery. Curr Protoc Pharmacol (2010) 1.12

Candidate pathways and genes for prostate cancer: a meta-analysis of gene expression data. BMC Med Genomics (2009) 1.11

Glycogen synthase kinase-3 beta is involved in the phosphorylation and suppression of androgen receptor activity. J Biol Chem (2004) 1.10